Tariff Warning on March 1, 2025
The one-month reprieve from U.S. President Trump’s tariffs on Mexico and Canada is nearing an end. Despite Mexico committing 10,000 troops to prevent illegal immigrant crossing, the President repeated yesterday that the tariffs are ‘on time.’Tariffs will harm exporting nations more than the country that imports more. Still, Americans will face higher import prices once Canada and Mexico retaliate. Furthermore, relations between Canada and the U.S. worsened since tariff threats started. Canadians cut back on buying American goods, reduced their travel, or canceled trips to states like Florida. This could hurt airline stocks like American Airlines (AAL). AAL stock peaked in January at around $19.00 and closed at $15.31. Beware of United Airlines (UAL) and Southwest Airlines (LUV) underperforming as well.The automobile sector will likely sink lower in the month ahead if tariffs proceed. Ford Motor (F), General Motors (GM), and Stellantis (STLA) risk trading at multi-year lows. Japanese auto firms like Toyota (TM) and Honda (HMC) are diversified away from North American markets but will still face higher costs. Auto parts move back and forth among the countries in USMCA.After the Canadian dollar (FXC) plunged below $68, it rallied back to $69. Markets thought that tariff risks dissipated but were wrong. In addition, the USD-CAD could fall below $0.67, taking the FXC ETF to new decade lows.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


